US-based clinical trial service provider Florence Healthcare has acquired VersaTrial in an effort to expedite research site enablement.
The acquisition is part of Florence Healthcare's aim to 'transform' the landscape of clinical research operations by enabling every study centre to increase its capacity.
It combines the complementary strengths of both companies in the e-clinical space to provide new solutions for research sites, contract research organisations (CROs) and sponsors.
Florence Healthcare and VersaTrial aim to enable access to real-time site connectivity for sites, sponsors and CROs in order to minimise data duplication, improve site readiness and increase communication across sites.
Florence Healthcare CEO Ryan Jones said: “This acquisition marks a significant moment for our industry.
“Together, VersaTrial and Florence have the opportunity to help every trial site do their best work and get this industry closer to maximising efficiency and capacity for every research site.”
Florence Healthcare will integrate VersaTrial’s solutions, which are designed to reduce tech burdens, speed up feasibility response times and improve communication across frequently changing study personnel.
VersaTrial’s clinical trial site engagement platform will allow CROs and sponsors access to bi-directional communication and real-time operational insights for measurable site oversight and quality execution.
VersaTrial CEO Mike Wenger said: “Joining forces with Florence Healthcare is a monumental leap forward for VersaTrial and for research sites globally.
“Florence Healthcare’s proven track record digitising clinical trial sites globally at scale will undoubtedly enhance the impact of our solutions.
“Together, we’re poised to drive meaningful improvements in trial speed and patient outcomes.”
Based in Nebraska, Florence Healthcare has more than 18,000 connected research sites in more than 55 countries and aims to streamline the process related to clinical trials.
VersaTrial is an all-in-one site solution designed to help sponsors and CROs improve clinical trial speed, quality and collaboration.
